Exogenous activation of BMP-2 signaling overcomes TGFβ-mediated inhibition of osteogenesis in marfan embryonic stem cells and marfan patient-specific induced pluripotent stem cells

Stem Cells

Volumn 30, Issue 12, 2012, Pages 2709-2719

  Quarto, Natalina ^a,b   Li, Shuli ^a   Renda, Andrea ^b   Longaker, Michael T ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bone; Embryonic stem cells; Induced pluripotent stem cells; Signal transduction

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ALKALINE PHOSPHATASE; BETA ACTIN; BONE MORPHOGENETIC PROTEIN 2; CYCLINE; FIBRILLIN 1; FIBROBLAST GROWTH FACTOR 2; MESSENGER RNA; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3;

ANIMAL CELL; ARTICLE; BONE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL LYSATE; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; EMBRYONIC STEM CELL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; GENE MUTATION; GENETIC DISORDER; HUMAN; HUMAN CELL; MARFAN SYNDROME; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PLURIPOTENT STEM CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKELETON;

BONE AND BONES; BONE MORPHOGENETIC PROTEIN 2; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; EMBRYONIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MARFAN SYNDROME; MICROFILAMENT PROTEINS; MUTATION; OSTEOGENESIS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84870325682     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1250     Document Type: Article

References (63)

1. Dietz HC, Loeys B, Carta L, et al. Recent progress towards a molecular understanding of Marfan syndrome. Am J Med Genet C Semin Med Genet 2005;139C:4-9.
2. Robinson PN, Arteaga-Solis E, Baldock C, et al. The molecular genetics of Marfan syndrome and related disorders. J Med Genet 2006;43:769-787.
3. Pyeritz RE, McKusick VA. The Marfan syndrome: Diagnosis and management. N Engl J Med 1979;300:772-777.
4. Pereira L, D'Alessio M, Ramirez F, et al. Genomic organization of the sequence coding for fibrillin, the defective gene product in Marfan syndrome. Hum Mol Genet 1993;2:961-968.
5. ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007;8:857-869.
6. Kaartinen V, Warburton D. Fibrillin controls TGF-beta activation. Nat Genet 2003;33:331-332.
7. Ramirez F, Sakai LY, Dietz HC, et al. Fibrillin microfibrils: Multipurpose extracellular networks in organismal physiology. Physiol Genomics 2004;19:151-154.
8. Kainulainen K, Pulkkinen L, Savolainen A, et al. Location on chromosome 15 of the gene defect causing Marfan syndrome. N Engl J Med 1990;323:935-939.
9. Dietz HC, Pyeritz RE, Hall BD, et al. The Marfan syndrome locus: Confirmation of assignment to chromosome 15 and identification of tightly linked markers at 15q15-q21.3. Genomics 1991;9:355-361.
10. Magenis RE, Maslen CL, Smith L, et al. Localization of the fibrillin (FBN) gene to chromosome 15, band q21.1. Genomics 1991;11:346-351.
11. Maslen CL, Corson GM, Maddox BK, et al. Partial sequence of a candidate gene for the Marfan syndrome. Nature 1991;352:334-337.
12. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991;352:337-339.
13. Dietz HC, Pyeritz RE, Puffenberger EG, et al. Marfan phenotype variability in a family segregating a missense mutation in the epidermal growth factor-like motif of the fibrillin gene. J Clin Invest 1992;89:1674-1680.
14. Dietz HC, Pyeritz RE. Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Hum Mol Genet 1995;4 Spec No:1799-1809.
15. Faivre L, Khau Van Kien P, Callier P, et al. De novo 15q21.1q21.2 deletion identified through FBN1 MLPA and refined by 244K array-CGH in a female teenager with incomplete Marfan syndrome. Eur J Med Genet 2010;53:208-212.
16. Matyas G, Alonso S, Patrignani A, et al. Large genomic fibrillin-1 (FBN1) gene deletions provide evidence for true haploinsufficiency in Marfan syndrome. Hum Genet 2007;122:23-32.
17. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006;312:117-121.
18. Ng CM, Cheng A, Myers LA, et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 2004;114:1586-1592.
19. Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003;33:407-411.
20. Quarto N, Leonard B, Li S, et al. Skeletogenic phenotype of human Marfan embryonic stem cells faithfully phenocopied by patient-specific induced-pluripotent stem cells. Proc Natl Acad Sci USA 2012;109:215-220.
21. Brooke BS, Habashi JP, Judge DP, et al. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008;358:2787-2795.
22. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005;37:275-281.
23. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006;355:788-798.
24. Pannu H, Fadulu VT, Chang J, et al. Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation 2005;112:513-520.
25. Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 2004;36:855-860.
26. Liu W, Schrijver I, Brenn T, et al. Multi-exon deletions of the FBN1 gene in Marfan syndrome. BMC Med Genet 2001;2:11.
27. Tuli R, Tuli S, Nandi S, et al. Characterization of multipotential mesenchymal progenitor cells derived from human trabecular bone. Stem Cells 2003;21:681-693.
28. Buhring HJ, Battula VL, Treml S, et al. Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci 2007;1106:262-271.
29. Quarto N, Longaker MT. Differential expression of specific FGF ligands and receptor isoforms during osteogenic differentiation of mouse adipose-derived stem cells (mASCs) recapitulates the in vivo osteogenic pattern. Gene 2008;424:130-140.
30. Quarto N, Fong KD, Longaker MT. Gene profiling of cells expressing different FGF-2 forms. Gene 2005;356:49-68.
31. Quarto N, Wan DC, Longaker MT. Molecular mechanisms of FGF-2 inhibitory activity in the osteogenic context of mouse adipose-derived stem cells (mASCs). Bone 2008;42:1040-1052.
32. Quarto N, Behr B, Li S, et al. Differential FGF ligands and FGF receptors expression pattern in frontal and parietal calvarial bones. Cells Tissues Organs 2009;190:158-169.
33. Levi B, Hyun JS, Nelson ER, et al. Nonintegrating knockdown and customized scaffold design enhances human adipose-derived stem cells in skeletal repair. Stem Cells 2011;29:2018-2029.
34. Quarto N, Wan DC, Kwan MD, et al. Origin matters: Differences in embryonic tissue origin and Wnt signaling determine the osteogenic potential and healing capacity of frontal and parietal calvarial bones. J Bone Miner Res 2010;25:1680-1694.
35. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425:577-584.
36. Massague J. TGFbeta in cancer. Cell 2008;134:215-230.
37. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003;100:8621-8623.
38. Inman GJ, Nicolas FJ, Callahan JF, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002;62:65-74.
39. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors 2004;22:233-241.
40. Alexandrow MG, Kawabata M, Aakre M, et al. Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor beta 1. Proc Natl Acad Sci USA 1995;92:3239-243.
41. Maeda S, Hayashi M, Komiya S, et al. Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J 2004;23:552-563.
42. Fierro FA, Kalomoiris S, Sondergaard CS, et al. Effects on proliferation and differentiation of multipotent bone marrow stromal cells engineered to express growth factors for combined cell and gene therapy. Stem Cells 2011;29:1727-1737.
43. Wozney JM, Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop Relat Res 1998:26-37.
44. Behr B, Sorkin M, Lehnhardt M, et al. A comparative analysis of the osteogenic effects of BMP-2, FGF-2, and VEGFA in a calvarial defect model. Tissue Eng Part A 2012;18:1079-1086.
45. Tang Y, Wu X, Lei W, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 2009;15:757-765.
46. Wrana JL, Maeno M, Hawrylyshyn B, et al. Differential effects of transforming growth factor-beta on the synthesis of extracellular matrix proteins by normal fetal rat calvarial bone cell populations. J Cell Biol 1988;106:915-924.
47. Wang S, Hirschberg R. BMP7 antagonizes TGF-beta -dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol 2003;284:F1006-F1013.
48. Giacomini D, Paez-Pereda M, Stalla J, et al. Molecular interaction of BMP-4, TGF-beta, and estrogens in lactotrophs: Impact on the Prl promoter. Mol Endocrinol 2009;23:1102-1114.
49. Keller B, Yang T, Chen Y, et al. Interaction of TGFbeta and BMP signaling pathways during chondrogenesis. PLoS One 2011;6:e16421.
50. Yew KH, Hembree M, Prasadan K, et al. Cross-talk between bone morphogenetic protein and transforming growth factor-beta signaling is essential for exendin-4-induced insulin-positive differentiation of AR42J cells. J Biol Chem 2005;280:32209-32217.
51. Wrighton KH, Lin X, Yu PB, et al. Transforming growth factor b can stimulate Smad1 phosphorylation independently of bone morphogenic protein receptors. J Biol Chem 2009;284:9755-9763.
52. Izumi N, Mizuguchi S, Inagaki Y, et al. BMP-7 opposes TGF-beta1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. Am J Physiol Lung Cell Mol Physiol 2006;290:L120-L126.
53. He XC, Zhang J, Tong WG, et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat Genet 2004;36:1117-1121.
54. Kobielak K, Stokes N, de la Cruz J, et al. Loss of a quiescent niche but not follicle stem cells in the absence of bone morphogenetic protein signaling. Proc Natl Acad Sci USA 2007;104:10063-10068.
55. Xu RH, Peck RM, Li DS, et al. Basic FGF and suppression of BMP signaling sustain undifferentiated proliferation of human ES cells. Nat Methods 2005;2:185-190.
56. Bonaguidi MA, Peng CY, McGuire T, et al. Noggin expands neural stem cells in the adult hippocampus. J Neurosci 2008;28:9194-9204.
57. Chaturvedi G, Simone PD, Ain R, et al. Noggin maintains pluripotency of human embryonic stem cells grown on Matrigel. Cell Prolif 2009;42:425-433.
58. Goumans MJ, Liu Z, ten Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res 2009;19:116-127.
59. Kaplan FS, Shen Q, Lounev V, et al. Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP). J Bone Miner Metab 2008;26:521-530.
60. Fukuda T, Kanomata K, Nojima J, et al. A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. Biochem Biophys Res Commun 2008;377:905-909.
61. Billings PC, Fiori JL, Bentwood JL, et al. Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res 2008;23:305-313.
62. Tiscornia G, Vivas EL, Belmonte JC. Diseases in a dish: Modeling human genetic disorders using induced pluripotent cells. Nat Med 2011;17:1570-1576.
63. Puri MC, Nagy A. Concise review: Embryonic stem cells versus induced pluripotent stem cells: the game is on. Stem Cells 2012;30:10-14.